Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy.

ABSTRACT:

Background

Lung cancer remains one of the most challenging diseases to treat due to its heterogeneity. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutations are genetic drivers in numerous cancer types including lung adenocarcinoma (LUAD). Despite recent advances in KRAS-targeted therapies, treatment resistance and limited therapeutic options necessitate advanced preclinical models, such as organoids, to identify personalized cancer therapies by screening novel therapeutic strategies and synergistic drug combinations.

Results

We established LUAD in genetically engineered mouse (GEM) models of Kras^G12V & Trp53 ^Δex2-10 (KP) and KP with Ctnnb1^Δex3 mutation (KPC). Tumor-derived organoids from these models recapitulated the genomic landscape

SUBMITTER: Tas I 

PROVIDER: S-EPMC12020293 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature